Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-Hepatobiliary Substudy 1 in hepatocellular carcinoma
CTR20230888Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of volrustomig in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Jun 2023; status: active.
02
Drugs
volrustomig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20230888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230888.